Study Demonstrates Effectiveness of Liraglutide in Obese Tee
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.

In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56.

Results: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56. A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group, and a reduction in BMI of at least 10% was observed in 33 and 9, respectively.

A greater reduction was observed with liraglutide than with placebo for BMI and for body weight. After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo. More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events and adverse events that led to discontinuation of the trial treatment. Few participants in either group had serious adverse events.

Conclusively, In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1916038?query=featured_pediatrics
1 share
Like
Comment
Share